{"nct_id":"NCT07081997","title":"A Phase 3 Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism","status":"NOT_YET_RECRUITING","status_verified_date":"2025-07","start_date":"2025-11","start_date_type":"ESTIMATED","primary_completion_date":"2026-12","primary_completion_date_type":"ESTIMATED","completion_date":"2027-12","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["ASND"]}